Aromatase inhibitors in breast cancer

Endocrine-Related Cancer

Volumn 11, Issue 2, 2004, Pages 179-189

  Lonning P E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; DIETHYLSTILBESTROL; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; PYRIDOGLUTETHIMIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VOROZOLE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PREVENTION; CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG STRUCTURE; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; HORMONE SENSITIVITY; HUMAN; PATIENT MONITORING; POSTMENOPAUSE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; HUMANS;

EID: 3042545132     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0110179     Document Type: Review

References (100)

1. Agarwal VR, Bulun SE, Leitch M, Rohrich R & Simpson ER 1996 Use of alternative promoters to express the aromatase cytochrome p450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. Journal of Clinical Endocrinology and Metabolism 81 3843-3849.
2. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML & Lanzino M 2002 Breast cancer: from estrogen to androgen receptor. Molecular and Cellular Endocrinology 193 121-128.
3. Bajetta E, Zilembo N, Bichisao E, Martinetti A, Buzzoni R, Pozzi P, Bidoli P, Ferrari L & Celio L 2000 Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. Annals of Oncology 11 1017-1022.
4. Batzl C, Hausler A, Schieweck K, Lang M & Trunet P 1996 Pharmacology of nonsteroidal aromatase inhibitors. In Hormone-Dependent Cancer, pp 155-168. Eds J Pasqualini & B Katzenellenbogen. New York: Marcel Dekker Inc.
5. Baum M, Buzdar AU, Cuzick J, Forbes J, Houghton J, Klijn JGM, Sahmoud T & Grp AT 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 2131-2139.
6. Binnie GG 1944 Regression of tumors following treatment by stilboestrol and X-ray therapy, with notes on cases of breast tumour which regressed with stilboestrol alone. British Journal of Radiology 17 42-45.
7. Bonneterre J, Thurlimann B, Robertson JFR, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M & von Euler M 2000 Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. Journal of Clinical Oncology 18 3748-3757.
8. Bonneterre J, Buzdar A, Nabholtz J-M, Robertson J, Thürlimann B, von Euler M, Sahmoud T, Webster A & Steinberg M 2001 Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 2247-2258.
9. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL & Yaffe MJ 1995 Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian national breast screening study. Journal of the National Cancer Institute 87 670-675.
10. Bulun SE, Price TM, Aitken J, Mahendroo MS & Simpson ER 1993 A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome p450 transcripts using competitive polymerase chain reaction after reverse transcription. Journal of Clinical Endocrinology and Metabolism 77 1622-1628.
11. Bulun SE, Fang ZJ, Gurates B, Tamura M, Yilmaz B, Amin S & Yang SJ 2003 Aromatase in health and disease. Endocrinologist 13 269-276.
12. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M & Cooper J 1996 Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Results of two randomized double blind controlled multiinstitutional trials. Cancer 77 2503-2513.
13. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A & Lee D 1998 Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 83 1142-1152.
14. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X & Brady C 2001 Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Journal of Clinical Oncology 19 3357-3366.
15. Carlini P, Frassoldati A, DeMarco S, Casali A, Ruggeri EM, Nardi M, Papaldo P, Fabi A, Paoloni F & Cognetti F 2001 Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? Annals of Oncology 12 1539-1543.
16. Chen SU, Zhou DJ, Yang C, Okubo T, Kinoshita Y, Yu B, Kao YC & Itoh T 2001 Modulation of aromatase expression in human breast tissue. Journal of Steroid Biochemistry and Molecular Biology 79 35-40.
17. Couzinet B, Meduri G, Lecce M, Young J, Brailly S, Loosfelt H, Milgrom E & Schaison G 2001 The postmenopausal ovary is not a major androgen-producing gland. Journal of Clinical Endocrinology and Metabolism 86 5060-5066.
18. Dirix L, Piccart MJ, Lohrish C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Yague C, Duchateau L, Lobelle J & Paridaens R 2001 Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proceedings of the American Society for Clinical Oncology 20 29a.
19. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U & Trunet PF 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
20. Dorgan JF, Longcope C, Franz C, Stanczyk FZ, Chang LC, Stephenson HE, Falk RT, Kahle L, Miller R, Tangrea JA, Campbell WS, Schatzkin A, Key TJ, Allen DS, Fentiman LS, Moore JW, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB & Miller SR 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 94 606-616.
21. Dowsett M, Harris AL, Smith IE & Jeffcoate SL 1984 Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. Journal of Clinical Endocrinology and Metabolism 58 99-104.
22. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH, Jeffcoate SL & Coombes RC 1987 Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Research 47 1957-1961.
23. Dowsett M, Mehta A, King N, Smith IE, Powles TJ, Stein RC & Coombes RC 1992 An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. European Journal of Cancer 28 415-420.
24. Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P & Smith IE 1995 In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in post menopausal patients with breast cancer. Clinical Cancer Research 1 1511-1515.
25. Edery M, Goussard J, Dehennin L, Scholler R, Reiffsteck J & Drosdowsky MA 1980 Endogenous oestradiol-17β concentration in breast tumours determined by mass fragmentography and by radioimmunoassay: relationship to receptor content. European Journal of Cancer 17 115-120.
26. Falkson CI & Falkson HC1996 A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer. Annals of Oncology 7 465-469.
27. Frisch RE, Canick JA & Tulchinsky D 1980 Human fatty marrow aromatizes androgen to estrogen. Journal of Clinical Endocrinology and Metabolism 51 394-396.
28. Furet P, Batzl C, Bhatnagar A, Francotte E, Rihs G & Lang M 1993 Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. Journal of Medical Chemistry 36 1393-1400.
29. Geisler J & Lønning P 2001 Resistance to endocrine therapy of breast cancer: recent advances and tomorrows challenges. Clinical Breast Cancer 1 297-308.
30. Geisler J, Johannessen DC, Anker G & Lønning PE 1996a Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. European Journal of Cancer 32A 789-792.
31. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO & Lønning PE 1996b Influence of anastrozole (Arimidex®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer 74 1286-1291.
32. Geisler J, Lien EA, Ekse D & Lønning PE 1997 Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Moleular Biology 63 53-58.
33. Geisler J, King N, Anker G, Ornati G, DiSalle E, Lønning PE & Dowsett M 1998 In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clinical Cancer Research 4 2089-2093.
34. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjorn B, Dowsett M & Lønning PE 2001 Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clinical Cancer Research 7 1230-1236.
35. Geisler J, Haynes B, Anker G, Dowsett M & Lønning PE 2002 Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. Journal of Clinical Oncology 20 751-757.
36. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P & Lassus M 1998 Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annals of Oncology 9 639-645.
37. Goss PE & Strasser K 2001 Aromatase inhibitors in the treatment and prevention of breast cancer. Journal of Clinical Oncology 19 881-894.
38. Haddow A, Watkinson JM & Paterson E 1944 Influence of synthetic oestrogens upon advanced malignant disease. British Medical Journal 2 393-398.
39. HarperWynne C & Coombes RC 1999 Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. European Journal of Cancer 35 744-746.
40. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A & Morris C 2002 Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 20 3396-3403.
41. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J & Frytak S 1981 Randomized clinical trial of diethylstilstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. New England Journal of Medicine 304 16-21.
42. Jacobs S, Lønning PE, Haynes B, Griggs L & Dowsett M 1991 Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. Journal of Enzyme Inhibition 4 315-325.
43. Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V & Samonigg H 2002 Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. Journal of Clinical Oncology 20 4621-4627.
44. James VHT, Reed MJ, Adams EF, Ghilchik M, Lai LC, Coldham NG, Newton CJ, Purohit A, Owen AM, Singh CJ & Islam S 1989 Oestrogen uptake and metabolism in vivo. Oestrogens and the human breast. Proceedings of the Royal Society of Edinburgh 95B 185-193.
45. Johannessen DC, Engan T, Salle Ed, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S & Lønning PE 1997 Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clinical Cancer Research 3 1101-1108.
46. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M & Lisboa B 2002 Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. Journal of Clinical Oncology 20 4628-4635.
47. Jones AL, MacNeill F, Jacobs S, Lønning PE, Dowsett M & Powles TJ 1992 The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. European Journal of Cancer 28A 1712-1716.
48. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn J-L, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, Di Salle E, Arkhipov A, Piscitelli G, Miller LL & Massimini G 2000 Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. Journal of Clinical Oncology 18 1399-1411.
49. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB & Miller SR 2003 Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute 95 1218-1226.
50. Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L & Sylvester R 2001 Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. Journal of Clinical Oncology 19 343-353.
51. van Landeghem AAJ, Poortman J, Nabuurs M & Thijssen JHH 1985 Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Research 45 2900-2904.
52. Lea OA, Kvinnsland S & Thorsen T 1989 Improved measurement of androgen receptors in human breast cancer. Cancer Research 49 7162-7167.
53. Lippman M, Bolan G & Huff K 1976 The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Research 36 4595-4601.
54. Lønning PE 1996 Pharmacology of new aromatase inhibitors. Breast 5 202-208.
55. Lønning PE 2001 Stepwise estrogen suppression manipulating the estrostat. Journal of Steroid Biochemistry and Molecular Biology 79 127-132.
56. Lønning PE 2002 Aromatase inhibitors and inactivators for breast cancer therapy. Drugs and Aging 19 277-298.
57. Lønning PE & Ekse D 1995 A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology 55 409-412.
58. Lønning PE, Dowsett M & Powles TJ 1990 Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. Journal of Steroid Biochemistry 35 355-366.
59. Lønning PE, Jacobs S, Jones A, Haynes B, Powles T & Dowsett M 1991 The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer 63 789-793.
60. Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A & Massimini G 2000 Activity of exemestane (Aromasin®) in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology 18 2234-2244.
61. Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen LM, Mella O & Howell A 2001 High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine treatment. Breast Cancer Research and Treatment 67 111-116.
62. MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ & Dowsett M 1992 The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer 66 692-697.
63. MacNeill FA, Jacobs S, Dowsett M, Lønning PE & Powles TJ 1995 The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemotherapy and Pharmacology 36 249-254.
64. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925.
65. Masamura S, Santner SJ, Gimotty P, George J & Santen RJ 1997 Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake. Breast Cancer Research and Treatment 42 215-226.
66. Matsumine H, Hirato K, Yanaihara T, Tamada T & Yoshida M 1984 Aromatization by skeletal muscle. Journal of Clinical Endocrinology and Metabolism 63 717-720.
67. Miller WR 1989 Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treatment Review 16 83-93.
68. Miller WR 1994 Importance of intratumour aromatase, and its susceptibility to inhibitors. In Aromatase Inhibition - Then, Now and Tomorrow, pp 43-53. Ed. M Dowsett. London: Parthenon Publishing Group.
69. Miller WR & Dixon JM 2000 Antiaromatase agents: preclinical data and neoadjuvant therapy. Clinical Breast Cancer 1 (Suppl 1) 9-14.
70. Miller WR & Dixon JM 2001 Local endocrine effects of aromatase inhibitors within the breast. Journal of Steroid Biochemistry and Molecular Biology 79 93-102.
71. Miller WR, Anderson TJ & Jack WJL 1990 Relationship between tumour aromatase activity, tumour characteristics and response to therapy. Journal of Steroid Biochemistry and Molecular Biology 37 1055-1059.
72. Miller WR, Telford J, Love C, Leonard RCF, Hillier S, Gundacker H, Smith H & Dixon JM 1998 Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. Breast 7 273-276.
73. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA & Dugan M 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 19 2596-2606.
74. Murray R & Pitt P 1995 Aromatase inhibition with 4OH-androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Research and Treatment 35 249-253.
75. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A & von Euler M 2000 Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Journal of Clinical Oncology 18 3758-3767.
76. Njar VCO & Brodie AMH 1999 Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 58 233-255.
77. Nosaquo ND 1960 Androgens and estrogens in the treatment of disseminated mammary carcinoma. Journal of the American Medical Association 172 135-147.
78. Perel E & Killinger DW 1978 The interconversion and aromatization of androgens by human adipose tissue. Journal of Steroid Biochemistry 10 623-627.
79. Perel E, Blackstein ME & Killinger DW 1982 Aromatase in human breast carcinoma. Cancer Research 42 (Suppl) 3369-3372.
80. Pérez-Carrión R, Candel VA, Calabresi F, Michel RT, Santos R, Delozier T, Goss P, Mauriac L, Feuilhade F, Freue M, Pannuti F, Belle SV, Martinez J, Wehrle E & Royce CM 1994 Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Annals of Oncology 5 (Suppl) 19-24.
81. Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ & St-Pierre MV 2003 Identification of steroid sulfate transport processes in the human mammary gland. Journal of Clinical Endocrinology and Metabolism 88 3902-3912.
82. Reed MJ, Owen AM, Lai LC, Coldham NG, Ghilchik MW, Shaikh NA & James VHT 1989 In situ oestrone synthesis in normal breast and breast tumour tissue; effect of treatment with 4-hydroxyandrostenedione. International Journal of Cancer 44 233-237.
83. Reed MJ, Aherne GW, Ghilchik MW, Patel S & Chakraborty J 1991 Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissue. International Journal of Cancer 49 562-565.
84. Reed MJ, Topping L, Coldham NG, Purohit A, Ghilchik MW & James VHT 1993 Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors. Journal of Steroid Biochemistry and Molecular Biology 44 589-596.
85. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E & Ruby E 1978 Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. Journal of Clinical Endocrinology and Metabolism 47 1257-1265.
86. Santen RJ, Worgul TJ, Lipton A, Harvey H & Boucher A 1982 Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Annals of Internal Medicine 96 94-101.
87. Santner SJ, Leszcynski D, Wright C, Manni A, Feil PD & Santen RJ 1986 Estrone sulfate: a potential source of estradiol in human breast cancer tissue. Breast Cancer Research and Treatment 7 35-44.
88. Schweikert HU, Milewich L & Wilson JD 1976 Aromatization of androstenedione by cultured human fibroblasts. Journal of Clinical Endocrinology and Metabolism 43 785-795.
89. Simpson E, Jones M, Davis S & Rubin G 1999 Do intracrine mechanisms regulate aromatase expression? Journal of Steroid Biochemistry and Molecular Biology 69 447-452.
90. Singh A, Purohit A, Ghilchik MW & Reed MJ 1999 The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. Endocrine-Related Cancer 6 139-147.
91. Sluijmer AV, Heineman MA, Jong FHD & Evers JLH 1995 Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. Journal of Clinical Endocrinology and Metabolism 80 2163-2167.
92. Smith IE & Dowsett M 2003 Drug therapy: aromatase inhibitors in breast cancer. New England Journal of Medicine 348 2431-2442.
93. Smuk M & Schwers J 1977 Aromatization of androstenedione by human adult liver in vitro. Journal of Clinical Endocrinology and Metabolism 45 1009-1012.
94. Thürlimann B, Beretta K, Bacchi M, Castiglionegertsch M, Goldhirsch A, Jungi WF, Cavalli F, Senn HJ, Fey M & Lohnert T 1996 First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer - prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Annals of Oncology 7 471-479.
95. Thürlimann B, Castiglione M, HsuSchmitz SF, Cavalli F, Bonnefoi H, Fey MF, Morant R, Lohnert T & Goldhirsch A 1997a Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). European Journal of Cancer 33 1017-1024.
96. Thürlimann B, Paridaens R, Serin D, Bonneterre J, Roche H, Murray R, diSalle E, Lanzalone S, Zurlo MG & Piscitelli G 1997b Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. European Journal of Cancer 33 1767-1773.
97. Vermeulen A, Deslypere JP, Paridaens R, Leclerco G, Roy F & Heuson JC 1985 Aromatase, 17β-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. European Journal of Cancer and Clinical Oncology 22 515-525.
98. Zhang YQ, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D & Felson DT 1997 Bone mass and the risk of breast cancer among postmenopausal women. New England Journal of Medicine 336 611-617.
99. Zhao Y, Mendelson CR & Simpson ER 1995 Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Molecular Endocrinology 9 340-349.
100. Zhao Y, Nichols JE, Valdez R, Mendelson CR & Simpson ER 1996 Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Molecular Endocrinology 10 1350-1357.